Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2005 | 5 |
2006 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV Clin Trials. 2005 Sep-Oct;6(5):254-61. doi: 10.1310/B5VU-FU5F-QNWC-UDCK.
HIV Clin Trials. 2005.
PMID: 16306032
Clinical Trial.
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.
Kappelhoff BS, et al.
Antivir Ther. 2005;10(1):145-55.
Antivir Ther. 2005.
PMID: 15751772
Clinical Trial.
Item in Clipboard
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
van Leth F, Huisamen CB, Badaro R, Vandercam B, de Wet J, Montaner JS, Hall DB, Wit FW, Lange JM; 2NN Study Group.
van Leth F, et al.
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
J Acquir Immune Defic Syndr. 2005.
PMID: 15735447
Clinical Trial.
Item in Clipboard
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
van Leth F, Conway B, Laplumé H, Martin D, Fisher M, Jelaska A, Wit FW, Lange JM; 2NN study group.
van Leth F, et al.
Antivir Ther. 2004 Oct;9(5):721-8.
Antivir Ther. 2004.
PMID: 15535409
Clinical Trial.
Item in Clipboard
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group.
Kappelhoff BS, et al.
Antivir Ther. 2005;10(4):489-98.
Antivir Ther. 2005.
PMID: 16038474
Item in Clipboard
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Leth FV, Kappelhoff BS, Johnson D, Losso MH, Boron-Kaczmarska A, Saag MS, Livrozet JM, Hall DB, Leith J, Huitema AD, Wit FW, Beijnen JH, Lange JM; 2NN Study Group.
Leth FV, et al.
AIDS Res Hum Retroviruses. 2006 Mar;22(3):232-9. doi: 10.1089/aid.2006.22.232.
AIDS Res Hum Retroviruses. 2006.
PMID: 16545009
Item in Clipboard
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J; 2NN study group.
van Leth F, et al.
AIDS. 2005 Mar 25;19(5):463-71. doi: 10.1097/01.aids.0000162334.12815.5b.
AIDS. 2005.
PMID: 15764851
Clinical Trial.
Item in Clipboard
Cite
Cite